Galluzzo Marco, Marcelli Lorenzo, Vellucci Laura, Paganini Claudia, Maffei Virginia, Tofani Lorenzo, Belcastro Alfredo, Bianchi Luca, Talamonti Marina
Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome, Italy.
Expert Opin Biol Ther. 2023 Apr;23(4):371-381. doi: 10.1080/14712598.2023.2194485. Epub 2023 Mar 27.
Real-world data are useful to guide the management of psoriasis. Here, we present data on the effectiveness and survival of guselkumab in moderate-to-severe chronic plaque psoriasis for up to 148 weeks.
Cross-sectional study of 122 patients receiving guselkumab (100 mg at weeks 0 and 4, and then every 8 weeks thereafter) for>12 weeks, from November 2018 to April 2022.
Clinical features and drug survival were analyzed up to 148 weeks.
Obese patients (32.8%) and those receiving prior biologics (64.8%) were included. Guselkumab treatment was associated with a rapid decrease in PASI, from 16.2 to 3.2 at week 12, and long-term improvements in all subgroups (97.6%, 82.9%, and 63.4% of patients, respectively, achieved PASI 75, 90, and 100 after 148 weeks). More non-obese than obese patients achieved PASI 100 at week 148 (86.4% vs 38.9%), as did bio-naïve vs bio-experienced patients (86.7% vs 50.0%). Previous biologic therapy was a negative prognostic factor for achieving PASI 100 over the long-term by multivariate analysis ( = 0.005). Overall, 96% of patients were on treatment after 2 years.
Real-world data confirm the long-term effectiveness of guselkumab in patients with psoriasis.
真实世界数据有助于指导银屑病的管理。在此，我们展示了古塞库单抗治疗中重度慢性斑块状银屑病长达148周的有效性和持续用药情况。
对2018年11月至2022年4月期间接受古塞库单抗治疗（第0周和第4周各100mg，之后每8周一次）超过12周的122例患者进行横断面研究。
分析长达148周的临床特征和药物持续用药情况。
纳入了肥胖患者（32.8%）和既往接受过生物制剂治疗的患者（64.8%）。古塞库单抗治疗与银屑病面积和严重程度指数（PASI）迅速下降相关，第12周时从16.2降至3.2，所有亚组均有长期改善（148周后分别有97.6%、82.9%和63.4%的患者达到PASI 75、90和100）。在第148周时，非肥胖患者达到PASI 100的比例高于肥胖患者（86.4%对38.9%），初治患者高于有生物制剂治疗经验的患者（86.7%对50.0%）。多因素分析显示，既往生物制剂治疗是长期达到PASI 100的阴性预后因素（P = 0.005）。总体而言，96%的患者在2年后仍在接受治疗。
真实世界数据证实了古塞库单抗治疗银屑病患者的长期有效性。
